# Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

> **NCT06468943** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 20 (estimated)

## Conditions studied

- Effects of Chemotherapy
- Safety Issues

## Interventions

- **DRUG:** Polatuzumab Vedotin
- **DRUG:** Zanubrutinib
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT06468943
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-07-01
- **Primary completion:** 2026-05-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06468943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06468943, "Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06468943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*